{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:23:20Z","timestamp":1788481400410,"version":"build-2803163510"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T00:00:00Z","timestamp":1532563200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000038","name":"Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN-2017-05020"],"award-info":[{"award-number":["RGPIN-2017-05020"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Gouvernement du Canada | Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP-111224"],"award-info":[{"award-number":["MOP-111224"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Triple-negative breast cancer (TNBC) is the most refractory subtype of breast cancer. It causes the majority of breast cancer-related deaths, which has been largely associated with the plasticity of tumor cells and persistence of cancer stem cells (CSCs). Conventional chemotherapeutics enrich CSCs and lead to drug resistance and disease relapse. Development of a strategy capable of inhibiting both bulk and CSC populations is an unmet medical need. Inhibitors against estrogen receptor 1, HDACs, or mTOR have been studied in the treatment of TNBC; however, the results are inconsistent. In this work, we found that patient TNBC samples expressed high levels of mTORC1 and HDAC genes in comparison to luminal breast cancer samples. Furthermore, co-inhibition of mTORC1 and HDAC with rapamycin and valproic acid, but neither alone, reproducibly promoted ESR1 expression in TNBC cells. In combination with tamoxifen (inhibiting ESR1), both S6RP phosphorylation and rapamycin-induced 4E-BP1 upregulation in TNBC bulk cells was inhibited. We further showed that fractionated CSCs expressed higher levels of mTORC1 and HDAC than non-CSCs. As a result, co-inhibition of mTORC1, HDAC, and ESR1 was capable of reducing both bulk and CSC subpopulations as well as the conversion of fractionated non-CSC to CSCs in TNBC cells. These observations were partially recapitulated with the cultured tumor fragments from TNBC patients. Furthermore, co-administration of rapamycin, valproic acid, and tamoxifen retarded tumor growth and reduced CD44<jats:sup>high\/+<\/jats:sup>\/CD24<jats:sup>low\/<\/jats:sup><jats:sup>\u2212<\/jats:sup> CSCs in a human TNBC xenograft model and hampered tumorigenesis after secondary transplantation. Since the drugs tested are commonly used in clinic, this study provides a new therapeutic strategy and a strong rationale for clinical evaluation of these combinations for the treatment of patients with TNBC.<\/jats:p>","DOI":"10.1038\/s41419-018-0811-7","type":"journal-article","created":{"date-parts":[[2018,7,26]],"date-time":"2018-07-26T10:58:38Z","timestamp":1532602718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Co-inhibition of mTORC1, HDAC and ESR1\u03b1 retards the growth of triple-negative breast cancer and suppresses cancer stem cells"],"prefix":"10.1038","volume":"9","author":[{"given":"Andrew","family":"Sulaiman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"McGarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ka Mien","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"El-Sahli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Kaczmarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Addison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Dimitroulakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Arnaout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Nessim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zemin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suresh","family":"Gadde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuguang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,26]]},"reference":[{"key":"811_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21332","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7\u201330 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"811_CR2","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1200\/JCO.2007.13.1748","volume":"26","author":"EA Rakha","year":"2008","unstructured":"Rakha, E. A., Reis-Filho, J. S. & Ellis, I. O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 26, 2568\u20132581 (2008).","journal-title":"J. Clin. Oncol."},{"key":"811_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent, R. et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 13, 4429\u20134434 (2007).","journal-title":"Clin. Cancer Res."},{"key":"811_CR4","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke, C. et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 26, 1275\u20131281 (2008).","journal-title":"J. Clin. Oncol."},{"key":"811_CR5","doi-asserted-by":"crossref","first-page":"771","DOI":"10.18632\/oncotarget.5819","volume":"7","author":"D Jia","year":"2016","unstructured":"Jia, D. et al. Cardamonin reduces chemotherapy-enriched breast cancer stem-like cells in vitro and in vivo. Oncotarget 7, 771 (2016).","journal-title":"Oncotarget"},{"key":"811_CR6","doi-asserted-by":"publisher","first-page":"e2932","DOI":"10.1038\/cddis.2017.319","volume":"8","author":"D Jia","year":"2017","unstructured":"Jia, D. et al. An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. Cell Death Dis. 8, e2932 (2017).","journal-title":"Cell Death Dis."},{"key":"811_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/2001-1326-2-3","volume":"2","author":"LN Abdullah","year":"2013","unstructured":"Abdullah, L. N. & Chow, E. K.-H. Mechanisms of chemoresistance in cancer stem cells. Clin. Transl. Med. 2, 3 (2013).","journal-title":"Clin. Transl. Med."},{"key":"811_CR8","unstructured":"Sulaiman, A., Yao, Z. & Wang, L. Re-evaluating the role of epithelial-mesenchymal-transition in cancer progression. J. Biomed. Res. 32, 81\u201390 (2017)."},{"key":"811_CR9","doi-asserted-by":"crossref","unstructured":"Sulaiman, A. et al. Dual inhibition of Wnt and Yes\u2010associated protein signaling retards the growth of triple negative breast cancer in both mesenchymal and epithelial states. Mol. Oncol. 12, 423\u2013430 (2018).","DOI":"10.1002\/1878-0261.12167"},{"key":"811_CR10","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.stemcr.2013.11.009","volume":"2","author":"S Liu","year":"2014","unstructured":"Liu, S. et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep. 2, 78\u201391 (2014).","journal-title":"Stem Cell Rep."},{"key":"811_CR11","doi-asserted-by":"publisher","first-page":"4606","DOI":"10.1002\/1873-3468.12496","volume":"590","author":"A Sulaiman","year":"2016","unstructured":"Sulaiman, A. et al. Both bulk and cancer stem cell subpopulations in triple\u2010negative breast cancer are susceptible to Wnt, HDAC, and ER\u03b1 coinhibition. FEBS Lett. 590, 4606\u20134616 (2016).","journal-title":"FEBS Lett."},{"key":"811_CR12","doi-asserted-by":"publisher","first-page":"113269","DOI":"10.18632\/oncotarget.22916","volume":"8","author":"A Sulaiman","year":"2017","unstructured":"Sulaiman, A. & Wang, L. Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors. Oncotarget 8, 113269\u2013113281 (2017).","journal-title":"Oncotarget"},{"key":"811_CR13","doi-asserted-by":"publisher","first-page":"7950","DOI":"10.1073\/pnas.1102454108","volume":"108","author":"CL Chaffer","year":"2011","unstructured":"Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. 108, 7950\u20137955 (2011).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"811_CR14","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1158\/1078-0432.CCR-15-1534","volume":"22","author":"P Wang","year":"2016","unstructured":"Wang, P. et al. Sensitive detection of mono-and polyclonal ESR1 mutations in primary tumors, metastatic lesions, and cell-free DNA of breast cancer patients. Clin. Cancer Res. 22, 1130\u20131137 (2016).","journal-title":"Clin. Cancer Res."},{"key":"811_CR15","first-page":"342","volume":"12","author":"JJ Lee","year":"2015","unstructured":"Lee, J. J., Loh, K. & Yap, Y.-S. PI3K\/Akt\/mTOR inhibitors in breast cancer. Cancer Biol. Med. 12, 342 (2015).","journal-title":"Cancer Biol. Med."},{"key":"811_CR16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.canlet.2012.03.034","volume":"323","author":"A Cavazzoni","year":"2012","unstructured":"Cavazzoni, A. et al. Overcoming acquired resistance to letrozole by targeting the PI3K\/AKT\/mTOR pathway in breast cancer cell clones. Cancer Lett. 323, 77\u201387 (2012).","journal-title":"Cancer Lett."},{"key":"811_CR17","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1158\/0008-5472.CAN-12-1248","volume":"72","author":"B Ramaswamy","year":"2012","unstructured":"Ramaswamy, B. et al. Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K\/AKT pathway. Cancer Res. 72, 5048\u20135059 (2012).","journal-title":"Cancer Res."},{"key":"811_CR18","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.neo.2014.03.008","volume":"16","author":"SM Singel","year":"2014","unstructured":"Singel, S. M. et al. KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. Neoplasia 16, 247\u2013256. e242 (2014).","journal-title":"Neoplasia"},{"key":"811_CR19","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10549-013-2630-y","volume":"140","author":"E Paplomata","year":"2013","unstructured":"Paplomata, E., Zelnak, A. & O\u2019Regan, R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res. Treat. 140, 453\u2013462 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"811_CR20","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1016\/j.celrep.2016.05.046","volume":"15","author":"JM Spangle","year":"2016","unstructured":"Spangle, J. M. et al. PI3K\/AKT signaling regulates H3K4 methylation in breast cancer. Cell Rep. 15, 2692\u20132704 (2016).","journal-title":"Cell Rep."},{"key":"811_CR21","doi-asserted-by":"publisher","first-page":"6592","DOI":"10.1128\/MCB.25.15.6592-6602.2005","volume":"25","author":"WC Huang","year":"2005","unstructured":"Huang, W.-C. & Chen, C.-C. Akt phosphorylation of p300 at Ser-1834 is essential for its histone acetyltransferase and transcriptional activity. Mol. Cell. Biol. 25, 6592\u20136602 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"811_CR22","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1227604","volume":"338","author":"K Xu","year":"2012","unstructured":"Xu, K. et al. EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science 338, 1465\u20131469 (2012).","journal-title":"Science"},{"key":"811_CR23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1172\/JCI44145","volume":"121","author":"SA Wander","year":"2011","unstructured":"Wander, S. A., Hennessy, B. T. & Slingerland, J. M. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J. Clin. Invest. 121, 1231\u20131241 (2011).","journal-title":"J. Clin. Invest."},{"key":"811_CR24","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","volume":"11","author":"J LoPiccolo","year":"2008","unstructured":"LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B. & Dennis, P. A. Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updat. 11, 32\u201350 (2008).","journal-title":"Drug Resist. Updat."},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1158\/1078-0432.CCR-06-2798","volume":"13","author":"RT Abraham","year":"2007","unstructured":"Abraham, R. T. & Gibbons, J. J. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin. Cancer Res. 13, 3109\u20133114 (2007).","journal-title":"Clin. Cancer Res."},{"key":"811_CR26","doi-asserted-by":"publisher","first-page":"17414","DOI":"10.1073\/pnas.0809136105","volume":"105","author":"AY Choo","year":"2008","unstructured":"Choo, A. Y., Yoon, S.-O., Kim, S. G., Roux, P. P. & Blenis, J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl Acad. Sci. 105, 17414\u201317419 (2008).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"811_CR27","doi-asserted-by":"publisher","first-page":"4949","DOI":"10.1128\/MCB.00383-09","volume":"29","author":"SJ Ellison-Zelski","year":"2009","unstructured":"Ellison-Zelski, S. J., Solodin, N. M. & Alarid, E. T. Repression of ESR1 through actions of estrogen receptor alpha and Sin3A at the proximal promoter. Mol. Cell. Biol. 29, 4949\u20134958 (2009).","journal-title":"Mol. Cell. Biol."},{"key":"811_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s12253-011-9423-6","volume":"18","author":"M Rasti","year":"2012","unstructured":"Rasti, M., Arabsolghar, R., Khatooni, Z. & Mostafavi-Pour, Z. p53 Binds to estrogen receptor 1 promoter in human breast cancer cells. Pathol. Oncol. Res. 18, 169\u2013175 (2012).","journal-title":"Pathol. Oncol. Res."},{"key":"811_CR29","doi-asserted-by":"publisher","first-page":"e68973","DOI":"10.1371\/journal.pone.0068973","volume":"8","author":"S Thomas","year":"2013","unstructured":"Thomas, S., Thurn, K. T., Raha, P., Chen, S. & Munster, P. N. Efficacy of histone deacetylase and estrogen receptor inhibition in breast cancer cells due to concerted down regulation of Akt. PLoS ONE 8, e68973 (2013).","journal-title":"PLoS ONE"},{"key":"811_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0533-z","volume":"17","author":"P Raha","year":"2015","unstructured":"Raha, P., Thomas, S., Thurn, K. T., Park, J. & Munster, P. N. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression. Breast Cancer Res. 17, 26 (2015).","journal-title":"Breast Cancer Res."},{"key":"811_CR31","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1038\/sj.onc.1207315","volume":"23","author":"ER Jang","year":"2004","unstructured":"Jang, E. R. et al. The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor \u03b1-negative breast cancer cells to tamoxifen. Oncogene 23, 1724 (2004).","journal-title":"Oncogene"},{"key":"811_CR32","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/ijc.30898","volume":"142","author":"P Nilendu","year":"2018","unstructured":"Nilendu, P., Kumar, A., Kumar, A., Pal, J. K. & Sharma, N. K. Breast cancer stem cells as last soldiers eluding therapeutic burn: a hard nut to crack. Int. J. Cancer 142, 7\u201317 (2018).","journal-title":"Int. J. Cancer"},{"key":"811_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s10549-014-3233-y","volume":"149","author":"P de Cremoux","year":"2015","unstructured":"de Cremoux, P. et al. HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts. Breast Cancer Res. Treat. 149, 81\u201389 (2015).","journal-title":"Breast Cancer Res. Treat."},{"key":"811_CR34","doi-asserted-by":"publisher","unstructured":"Lyn-Cook, B. D., Getz, J., Word, B., Moore, R. & Miranda-Carboni, G. (AACR, 2017). https:\/\/doi.org\/10.1158\/1538-7445.AM2017-18","DOI":"10.1158\/1538-7445.AM2017-18"},{"key":"811_CR35","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10555-014-9504-6","volume":"33","author":"MF Ziauddin","year":"2014","unstructured":"Ziauddin, M. F., Hua, D. & Tang, S.-C. Emerging strategies to overcome resistance to endocrine therapy for breast cancer. Cancer Metastasis Rev. 33, 791\u2013807 (2014).","journal-title":"Cancer Metastasis Rev."},{"key":"811_CR36","doi-asserted-by":"publisher","first-page":"2559","DOI":"10.1158\/1535-7163.MCT-13-1086","volume":"13","author":"K Dayekh","year":"2014","unstructured":"Dayekh, K. et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol. Cancer Ther. 13, 2559\u20132571 (2014).","journal-title":"Mol. Cancer Ther."},{"key":"811_CR37","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao, J. et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6, pl1 (2013).","journal-title":"Sci. Signal."},{"key":"811_CR38","doi-asserted-by":"crossref","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Dis. 2, 401\u2013404 (AACR, 2012).","DOI":"10.1158\/2159-8290.CD-12-0095"},{"key":"811_CR39","doi-asserted-by":"publisher","first-page":"D991","DOI":"10.1093\/nar\/gks1193","volume":"41","author":"T Barrett","year":"2012","unstructured":"Barrett, T. et al. NCBI GEO: archive for functional genomics data sets\u2014update. Nucleic Acids Res. 41, D991\u2013D995 (2012).","journal-title":"Nucleic Acids Res."},{"key":"811_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1093\/nar\/30.1.207","volume":"30","author":"R Edgar","year":"2002","unstructured":"Edgar, R., Domrachev, M. & Lash, A. E. Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res. 30, 207\u2013210 (2002).","journal-title":"Nucleic Acids Res."},{"key":"811_CR41","doi-asserted-by":"publisher","first-page":"e0122333","DOI":"10.1371\/journal.pone.0122333","volume":"10","author":"S Maubant","year":"2015","unstructured":"Maubant, S. et al. Transcriptome analysis of Wnt3a-treated triple-negative breast cancer cells. PLoS ONE 10, e0122333 (2015).","journal-title":"PLoS ONE"},{"key":"811_CR42","doi-asserted-by":"publisher","first-page":"e63712","DOI":"10.1371\/journal.pone.0063712","volume":"8","author":"V Maire","year":"2013","unstructured":"Maire, V. et al. TTK\/hMPS1 is an attractive therapeutic target for triple-negative breast cancer. PLoS ONE 8, e63712 (2013).","journal-title":"PLoS ONE"},{"key":"811_CR43","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1158\/0008-5472.CAN-12-2633","volume":"73","author":"V Maire","year":"2013","unstructured":"Maire, V. et al. Polo-like kinase 1: a potential therapeutic option in combination with conventional chemotherapy for the management of patients with triple-negative breast cancer. Cancer Res. 73, 813\u2013823 (2013).","journal-title":"Cancer Res."},{"key":"811_CR44","doi-asserted-by":"crossref","first-page":"4","DOI":"10.12688\/f1000research.1-4.v1","volume":"1","author":"M Livingstone","year":"2012","unstructured":"Livingstone, M. & Bidinosti, M. Rapamycin-insensitive mTORC1 activity controls eIF4E: 4E-BP1 binding. F1000Res. 1, 4 (2012).","journal-title":"F1000Res"},{"key":"811_CR45","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1523\/JNEUROSCI.23-06-02333.2003","volume":"23","author":"KT Akama","year":"2003","unstructured":"Akama, K. T. & McEwen, B. S. Estrogen stimulates postsynaptic density-95 rapid protein synthesis via the Akt\/protein kinase B pathway. J. Neurosci. 23, 2333\u20132339 (2003).","journal-title":"J. Neurosci."},{"key":"811_CR46","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","volume":"10","author":"WE Friedrichs","year":"2004","unstructured":"Friedrichs, W. E. et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin. Cancer Res. 10, 8059\u20138067 (2004).","journal-title":"Clin. Cancer Res."},{"key":"811_CR47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.12998\/wjcc.v2.i12.732","volume":"2","author":"K Miyai","year":"2014","unstructured":"Miyai, K. et al. Adenoid cystic carcinoma of breast: recent advances. World J. Clin. Cases 2, 732 (2014).","journal-title":"World J. Clin. Cases"},{"key":"811_CR48","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1073\/pnas.0530291100","volume":"100","author":"M Al-Hajj","year":"2003","unstructured":"Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. 100, 3983\u20133988 (2003).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"811_CR49","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/nm.2454","volume":"17","author":"YS DeRose","year":"2011","unstructured":"DeRose, Y. S. et al. Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes. Nat. Med. 17, 1514\u20131520 (2011).","journal-title":"Nat. Med."},{"key":"811_CR50","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies, C. et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381, 805\u2013816 (2013).","journal-title":"Lancet"},{"key":"811_CR51","doi-asserted-by":"crossref","unstructured":"Wilcken, N., Hornbuckle, J. & Ghersi, D. Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst. Rev. CD002747 (2003).","DOI":"10.1002\/14651858.CD002747"},{"key":"811_CR52","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10549-013-2629-4","volume":"140","author":"F Petrelli","year":"2013","unstructured":"Petrelli, F. et al. Five or more years of adjuvant endocrine therapy in breast cancer: a meta-analysis of published randomised trials. Breast Cancer Res. Treat. 140, 233\u2013240 (2013).","journal-title":"Breast Cancer Res. Treat."},{"key":"811_CR53","doi-asserted-by":"crossref","first-page":"29328","DOI":"10.18632\/oncotarget.16440","volume":"8","author":"H Ma","year":"2017","unstructured":"Ma, H. et al. Z-ligustilide restores tamoxifen sensitivity of ER\u03b1 negative breast cancer cells by reversing MTA1\/IFI16\/HDACs complex mediated epigenetic repression of ER\u03b1. Oncotarget 8, 29328 (2017).","journal-title":"Oncotarget"},{"key":"811_CR54","first-page":"6890","volume":"60","author":"X Yang","year":"2000","unstructured":"Yang, X. et al. Transcriptional activation of estrogen receptor \u03b1 in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 60, 6890\u20136894 (2000).","journal-title":"Cancer Res."},{"key":"811_CR55","doi-asserted-by":"publisher","first-page":"e74525","DOI":"10.1371\/journal.pone.0074525","volume":"8","author":"K Stark","year":"2013","unstructured":"Stark, K. et al. Reactivation of estrogen receptor \u03b1 by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor. PLoS ONE 8, e74525 (2013).","journal-title":"PLoS ONE"},{"key":"811_CR56","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.bbrc.2016.01.022","volume":"470","author":"H Noh","year":"2016","unstructured":"Noh, H., Park, J., Shim, M. & Lee, Y. Trichostatin A enhances estrogen receptor-alpha repression in MCF-7 breast cancer cells under hypoxia. Biochem. Biophys. Res. Commun. 470, 748\u2013752 (2016).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"811_CR57","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1210\/me.2015-1184","volume":"29","author":"L Ma","year":"2015","unstructured":"Ma, L. et al. HDAC5-mTORC1 interaction in differential regulation of ghrelin and nucleobindin 2 (NUCB2)\/nesfatin-1. Mol. Endocrinol. 29, 1571\u20131580 (2015).","journal-title":"Mol. Endocrinol."},{"key":"811_CR58","doi-asserted-by":"publisher","first-page":"e1002243","DOI":"10.1371\/journal.pbio.1002243","volume":"13","author":"S Wang","year":"2015","unstructured":"Wang, S. et al. Insulin and mTOR pathway regulate HDAC3-mediated deacetylation and activation of PGK1. PLoS Biol. 13, e1002243 (2015).","journal-title":"PLoS Biol."},{"key":"811_CR59","doi-asserted-by":"publisher","first-page":"10943","DOI":"10.1074\/jbc.M007758200","volume":"276","author":"YP Jiang","year":"2001","unstructured":"Jiang, Y.-P., Ballou, L. M. & Lin, R. Z. Rapamycin-insensitive regulation of 4e-BP1 in regenerating rat liver. J. Biol. Chem. 276, 10943\u201310951 (2001).","journal-title":"J. Biol. Chem."},{"key":"811_CR60","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/onc.2013.92","volume":"33","author":"GS Ducker","year":"2014","unstructured":"Ducker, G. S. et al. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene 33, 1590\u20131600 (2014).","journal-title":"Oncogene"},{"key":"811_CR61","doi-asserted-by":"publisher","first-page":"15050","DOI":"10.1074\/jbc.M311932200","volume":"279","author":"Xf Liu","year":"2004","unstructured":"Liu, X.-f & Bagchi, M. K. Recruitment of distinct chromatin-modifying complexes by tamoxifen-complexed estrogen receptor at natural target gene promoters in vivo. J. Biol. Chem. 279, 15050\u201315058 (2004).","journal-title":"J. Biol. Chem."},{"key":"811_CR62","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.canlet.2015.07.017","volume":"367","author":"GM Karthik","year":"2015","unstructured":"Karthik, G.-M. et al. mTOR inhibitors counteract tamoxifen-induced activation of breast cancer stem cells. Cancer Lett. 367, 76\u201387 (2015).","journal-title":"Cancer Lett."},{"key":"811_CR63","doi-asserted-by":"publisher","first-page":"18139","DOI":"10.1074\/jbc.C110.131599","volume":"285","author":"X Xu","year":"2010","unstructured":"Xu, X., Vatsyayan, J., Gao, C., Bakkenist, C. J. & Hu, J. HDAC2 promotes eIF4E sumoylation and activates mRNA translation gene specifically. J. Biol. Chem. 285, 18139\u201318143 (2010).","journal-title":"J. Biol. Chem."},{"key":"811_CR64","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/sj.bjc.6604634","volume":"99","author":"M Scandlyn","year":"2008","unstructured":"Scandlyn, M., Stuart, E., Somers-Edgar, T., Menzies, A. & Rosengren, R. A new role for tamoxifen in oestrogen receptor-negative breast cancer when it is combined with epigallocatechin gallate. Br. J. Cancer 99, 1056 (2008).","journal-title":"Br. J. Cancer"},{"key":"811_CR65","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0167-4781(83)90054-4","volume":"739","author":"JR Pasqualini","year":"1983","unstructured":"Pasqualini, J. R., Cosquer-Clavreul, C. & Gelly, C. Rapid modulation by progesterone and tamoxifen of estradiol effects on nuclear histone acetylation in the uterus of the fetal guinea pig. Biochim. Biophys. Acta 739, 137\u2013140 (1983).","journal-title":"Biochim. Biophys. Acta"},{"key":"811_CR66","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/15384101.2015.1127471","volume":"15","author":"X Ning","year":"2016","unstructured":"Ning, X. et al. Bulk pancreatic cancer cells can convert into cancer stem cells (CSCs) in vitro and 2 compounds can target these CSCs. Cell Cycle 15, 403\u2013412 (2016).","journal-title":"Cell Cycle"},{"key":"811_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/bcr3557","volume":"15","author":"E Karlsson","year":"2013","unstructured":"Karlsson, E. et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res. 15, R96 (2013).","journal-title":"Breast Cancer Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0811-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0811-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:16:31Z","timestamp":1671538591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-018-0811-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,26]]},"references-count":67,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,8]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1038\/s41419-018-0811-7","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,26]]},"assertion":[{"value":"14 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"815"}}